Cargando…

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates

Detalles Bibliográficos
Autores principales:	Gao, G, Peachman, KK, Wieczorek, L, Polonis, V, Alving, CR, Rao, M, Rao, VB
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441691/ http://dx.doi.org/10.1186/1742-4690-9-S2-P10

Ejemplares similares

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
por: Peachman, K, et al.
Publicado: (2009)

Cross-clade neutralization of HIV-1 by a monoclonal antibody obtained by immunization with liposomes containing lipid A and a synthetic MPER peptide
por: Matyas, GR, et al.
Publicado: (2012)

P04-22. Multispecific monoclonal antibodies bind to primary human macrophages and induce the production of protective chemokines, MIP-1α and MIP-1β
por: Weaver, KL, et al.
Publicado: (2009)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay
por: Rao, M, et al.
Publicado: (2012)

P12-08. Membrane-specific antibodies that simultaneously bind to gp41 of HIV-1 and membrane lipid epitopes are induced by immunization with liposomes
por: Beck, Z, et al.
Publicado: (2009)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Neutralization and enhancement of trans infection by erythrocyte-bound HIV with antibodies and complement
por: Beck, Z, et al.
Publicado: (2012)

Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development
por: Polonis, V, et al.
Publicado: (2012)

P19-41. Full-length IMC expressing Renilla luciferase for neutralization assay using PBMC
por: Chenine, A, et al.
Publicado: (2009)

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination
por: Sharma, SK, et al.
Publicado: (2012)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

Human Erythrocytes Selectively Bind and Enrich Infectious HIV-1 Virions
por: Beck, Zoltan, et al.
Publicado: (2009)

Virus-like particles highly expressing DC-SIGN concentrate trimeric HIV-envelope proteins with noncovalently linked immunoreactive gp120 and gp41
por: Vyas, GN
Publicado: (2012)

Immunisation with the membrane proximal external region of gp41 of HIV-1 grafted into the transmembrane envelope protein of a gammaretrovirus
por: Strasz, N, et al.
Publicado: (2012)

P09-13. Structure of HIV-1 gp41 interactive region: layered architecture and basis of conformational mobility
por: Pancera, M, et al.
Publicado: (2009)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
por: Scott, JK, et al.
Publicado: (2012)

Anti-gp41 antibodies inhibit infection and transcytosis of HIV-1 infectious molecular clones expressing transmitted/founder envelopes
por: Jain, S, et al.
Publicado: (2012)

P12-14. Design of hydrophilic, helical peptides that mimic the 4E10 epitope of HIV-1 gp41
por: Lorenz, IC, et al.
Publicado: (2009)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

Antigenicity of soluble HIV gp140 trimers reveals differences in solution conformation for differing HIV strains
por: Gearhart, TL, et al.
Publicado: (2012)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

Deep sequencing reveals an association between HIV-1 subtype C mutations in gp41 MPER epitopes and mother-to-child transmission
por: Yin, L, et al.
Publicado: (2012)

P10-09. Altered release of RANTES from human, normal platelets: contribution of distinct HIV-1MN gp41 peptides
por: Cognasse, F, et al.
Publicado: (2009)

P12-04. Topology of the C-terminal tail of HIV-1 gp41: Differential exposure of the Kennedy epitope on cell and viral membranes
por: Steckbeck, JD, et al.
Publicado: (2009)

The emptied bacteriophage T4 head: a novel nanoparticle vehicle to simultaneously deliver HIV-1 antigens and genes into dendritic cells
por: Rao, V
Publicado: (2012)

P05-13. Fragments of HIV-1 gp41 derivatives presented on virus-like particles with preserved binding affinity for broadly neutralizing antibodies
por: Benen, T, et al.
Publicado: (2009)

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 determinant for neutralization but not for antigen recognition
por: Weissenhorn, W, et al.
Publicado: (2012)

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1
por: Kessans, SA, et al.
Publicado: (2009)

The soluble guanylyl cyclase stimulator BAY 41-2272 increases differentiation and function of brown adipocytes
por: Etzrodt, Jennifer, et al.
Publicado: (2013)

The impact of differences in viral entry and trafficking on the mechanism of HIV-1 neutralization
por: Cincotta, CD Macedo, et al.
Publicado: (2012)

P04-39. Recognizing a dynamic HIV-1 target: a structural look at the interaction between bnAb 2F5 and varying gp41 MPER sequences
por: Julien, J, et al.
Publicado: (2009)

P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay
por: Bonsignori, M, et al.
Publicado: (2009)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

Mutational analysis of HIV-1 gp41 mediated apoptosis and its correlation with fusion/hemifusion
por: Garg, Himanshu, et al.
Publicado: (2006)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

P05-07. Evaluation of peripheral and bone marrow B cell responses in rhesus macaques after immunization with soluble HIV-1 gp140 trimers
por: Sundling, C, et al.
Publicado: (2009)

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_st2921so3s71312p7945gfn3l6